Genmab is actively seeking partners interested in developing potent antibody therapeutics incorporating the HexaBody® technology

Genmab is particularly interested in the possibility of participating in development of products in oncology and hematology that utilize the HexaBody technology, in addition to providing commercial technology licenses in exchange for upfront payments, milestones and royalties.

Therapeutics based on potency enhancing antibody technology, such as the HexaBody technology, have potential application in multiple disease areas. We believe this makes the HexaBody technology of broad interest to potential partners. To facilitate evaluation of the HexaBody technology before making a commitment to clinically develop and commercialize a product, Genmab can also provide research licenses. These licenses permit in-depth investigation of multiple HexaBody product concepts in a non-clinical setting. 

Click here for more information.